解郁丸合用氟西汀治疗重性抑郁障碍的对照研究

Study of Jieyu Wan Combined with Fluoxetine in the Treament of Major Depression Disorders

目的评价解郁丸合用氟西汀治疗重性抑郁障碍的疗效和安全性。方法将符合重性抑郁障碍诊断标准的74例住院患者随机分为两组,分别给予解郁丸合用氟西汀(38例)及单用氟西汀(36例)治疗6周,于治疗前和治疗后2、4、6周使用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、临床疗效总评量表的病情严重程度(CGI-SI)、副反应量表(TESS)评定疗效和不良反应。结果治疗6周后两组HAMD、HAMA评分较治疗前差异有非常显著性(t=10.62～13.70,P<0.01);两组间2、4、6周HAMD评分及4、6周HAMA评分差异有显著性(t=2.27～4.61,P<0.05～P<0.01);研究组有效率87%,对照组有效率67%,差异有显著性(t=4.25,P<0.05);两组间TESS评分差异有显著性(t=2.31,P<0.05)。结论解郁丸合用氟西汀治疗重性抑郁障碍疗效较好,安全性高。

Objective To explore curative effect and safety of jieyu wan combined with fluoxetine in the treatment of major depressive disorder.Methods A total of 74 in-patients with the diagnosis of major depressive disorder were randomly assigned to research（jieyu wan combined with fluoxetine,n=38 ） and control groups （single amitriptyline,n=36） for 6 weeks. The curative effect and adverse reactions were evaluated with HAMD,HAMA,CGI-SI and TESS before and in the 1st,2nd,4rd and 6th week during treatment.Results After 6 week treatment,scores of the HAMD and HAMA of both 2 groups were significant differences from those of pre-treatment （t=10.62～13.70,P0.01）; the scores of HAMD after 2,4 and 6 weeks and those of HAMA after 4 and 6 weeks showed significant differences between the 2 groups （t=2.27～4.61,P0.05～P0.01）; effective rate of research group was 87% and that of the control 67%,which showed significant difference（t=4.25,P0.05）;There were significant differences in clinical effects and side reactions between the 2 groups（t=2.31,P0.05）.Conclusion Jieyu wan combined with fluoxetine has better curative effect and higher safety in the treatment of major depressive disorder.